{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"8"}],"units":"Participants"}],"groups":[{"description":"5 mg of Pomalidomide Daily days 1 - 21. 40 mg Dexamethasone On days 1, 8. 15, 22. 4mcg/kg of Zarxio (G-CSF) Days 22- 28.","id":"OG000","title":"Maximum Tolerated Dose (MTD)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Data provided for the Participants who received MTD","reportingStatus":"POSTED","timeFrame":"Up to 28 days","title":"Number of Participants Recommended Phase II Dose of Pomalidomide and Dexamethasone, When Both Agents Are Administered Together With Granulocyte-colony Stimulating Factor (Filgrastim) (Phase I)","type":"PRIMARY","unitOfMeasure":"Participants"}